Breaking News
Ginkgo Bioworks
About Ginkgo Bioworks
Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. The company’s cell programming platform is enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including community testing, epidemiological tracing, vaccine development and therapeutics discovery.
Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies
April 13 2023
The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University […]
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
January 9 2023
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks, which […]
Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda
August 12 2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development […]
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks
August 12 2022
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases […]
Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors
August 5 2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy […]
Ginkgo to Acquire Zymergen
July 26 2022
Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and […]
Concentric by Ginkgo Crosses 10 Million Samples Tested and Expands Testing and Sequencing Capabilities to Detect Monkeypox and Other Pathogens, as Part of Scaling Its Global Biosecurity Infrastructure
June 27 2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced plans to further […]
Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products
June 8 2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo […]
Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform
June 7 2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has […]
Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar
May 19 2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a […]
Twist Bioscience and Ginkgo Bioworks Sign New Collaboration
April 7 2022
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality […]
Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics
April 5 2022
Microba Life Sciences (ASX:MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform […]
Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines Using Synthetic Biology
August 13 2021
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the […]
Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines
August 11 2021
Aldevron, a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, […]